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This study investigates the relative effects of low-
dose solar-simulated ultraviolet, ultraviolet A, and
ultraviolet B radiation on the elicitation of contact
hypersensitivity to nickel in nickel-allergic volunteers.
A xenon arc lamp with changeable filters was used to
irradiate groups of volunteers daily, on separate areas of
their lower backs, with both solar-simulated ultraviolet
(ultraviolet B, ultraviolet AII F ultraviolet AI) and
ultraviolet A (same ultraviolet AII content but twice
the ultraviolet AI as the solar-simulated ultraviolet
spectrum) for 1 and 2 d; 3, 4, and 5 d; and from 1 to
4 wk. A fourth group was irradiated for 1–5 d with the
ultraviolet B component of solar-simulated ultraviolet.
Following the final irradiation in each group, nickel-
containing patches were applied to both ultraviolet-
treated sites and adjacent, unirradiated control sites.
Erythema caused by nickel contact hypersensitivity at
each site was quantitated 72 h later with a reflectance
erythema meter. By comparing the nickel reactions of
irradiated and unirradiated skin, ultraviolet immuno-
Whereas the suppressive effects of ultraviolet (UV)radiation on human cutaneous immunity havebeen recognized for many years (Hersey et al,1983; Cooper et al, 1985; Murphy et al, 1993),the relative immunosuppressive contribution of
UVB (290–320 nm) and UVA (320–400 nm) is as yet unknown.
Most previous work has concentrated on UVB-induced immuno-
suppression and relatively few studies in humans have directly
examined the immune effects of UVA. Even fewer have directly
compared UVA and UVB in the same model. UVA is known to
have a number of deleterious effects on the skin, including genetic
mutation (Burren et al, 1998; de Laat et al, 1997), reduced
Langerhans cell activity (Aberer et al, 1981) isomerization of trans-
urocanic acid (Webber et al, 1997) and generation of oxygen free
radicals (Black, 1987), but the exact role of UVA in immunosuppres-
sion is still controversial.
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suppression was assessed with the different spectra
and durations of ultraviolet exposure. We found
significant immunosuppression with daily doses of
ultraviolet B and ultraviolet A equivalent to approxi-
mately 6 min of summer sun exposure, and that
ultraviolet A and ultraviolet B exerted their maximal
immunosuppressive effects at different times. Solar-
simulated ultraviolet-induced immunosuppression
was significant after one exposure, near-maximal after
two exposures and remained elevated thereafter. Ultra-
violet B-induced immunosuppression was lower than
that induced by solar-simulated ultraviolet, but fol-
lowed a similar time-course. In contrast, ultraviolet
A-induced immunosuppression was transient, peaking
after three exposures. Immune responses returned
towards normal with subsequent ultraviolet A expo-
sure, suggesting that an adaptive mechanism may
prevent immunosuppression by continued ultraviolet
A irradiation. Key words: immunosuppression/nickel
allergy/sunlight/ultraviolet radiation. J Invest Dermatol
112:939–944, 1999
Some groups have found that UVA has significant suppressive
effects on primary contact hypersensitivity (CHS) (Hersey et al,
1983; LeVee et al, 1997) but others have not (Skov et al, 1997).
Whereas UVA-induced suppression of delayed-type hypersensitivity
(DTH) responses to recall antigens has been reported (Hersey et al,
1987; Moyal et al, 1997), Sjo¨vall and Christensen (1986) found
that elicitation of CHS to nickel was suppressed by UVB but
not UVA.
In all of these human studies and in most murine studies, there
has been a tendency to use large and often erythemal doses of UVA
in order to achieve ‘‘biologic equivalence’’ with UVB. Erythemal
equivalence, however, does not imply immunosuppressive equival-
ence. It has been shown by our group and others that dark-
skinned subjects are just as susceptible as pale-skinned subjects to
immunosuppression by a given UV dose, whereas the erythemal
susceptibility of the two groups will be markedly different (Vermeer
et al, 1991; Damian et al, 1997).
There is also some evidence to suggest that high- and low-dose
UVA might exert opposite effects on cutaneous immunity. Recent
work by Reeve et al (1998) in hairless mice found that a single
high-dose UVA exposure reversed the immunosuppressive effect
of UVB radiation immediately preceding or following it, and that
UVA was more immune protective in higher doses. This contrasts
with the results of Bestak and Halliday (1996) who found significant
immunosuppression in C3H/HeJ mice when UVA was given for
940 DAMIAN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
4 wk at a low daily dose. Thus the relative immunosuppressive
effect of chronic vs. acute UV exposure is also unclear.
Allergy to nickel (in earrings, watchbands, and other costume
jewellery) is common in the general population and we have
previously shown that elicitation of nickel CHS is readily suppressed
by suberythemal solar-simulated UV (SSUV); this represents
immune suppression rather than suppression of nonspecific
inflammation, as UV exposure had no effect on patch test responses
to the nonspecific irritant, sodium lauryl sulfate (Damian et al,
1997). We also found that UV suppression of nickel CHS was only
prevented by sunscreens containing UVA as well as UVB filters,
thus suggesting indirectly that acute, low-dose UVA may be
immunosuppressive. Using this method to measure the relative
effects of low-dose UVB, UVA, and SSUV, we found that all were
immunosuppressive, but that their time-courses of immunosuppres-
sion were different. We also report that acute UVA exposure may
be more immunosuppressive than chronic exposure.
MATERIALS AND METHODS
Subjects Sixty healthy, nickel-allergic volunteers (59 female, one male)
of Fitzpatrick’s skin types I–V (Fitzpatrick, 1988) were recruited from the
local university (students and staff), hospital staff, and general population.
A further 12 volunteers (six men and six women), who were not necessarily
allergic to nickel, were recruited for minimal erythema dose (MED) testing
with the UVB-only source in order to determine its erythemal equivalence
with respect to the SSUV source.
None of the volunteers had experienced sun exposure of their backs for
at least 4 wk preceding the study. Ethical approval was obtained for these
experiments from both the Sydney University and Royal Prince Alfred
Hospital Ethics Committees, and all volunteers provided written informed
consent prior to entry into the study.
Nickel patch testing Nickel allergy was initially confirmed by patch
testing with 9 mm Finn chambers (Epitest, Tuusula, Finland). Each
volunteer was tested with at least three concentrations of NiS04.6 H20 in
a petrolatum base (Trolab Hermal, Reinbek, Germany) from 0.03125% to
2%, and a placebo patch, containing only petrolatum, was also included in
the test array. For each volunteer, the three nickel concentrations were
chosen according to the reported severity of their allergy, in order to
minimize the risk of unduly large reactions. For example, subjects reporting
only minimal symptoms after prolonged contact with costume jewellery
were tested with 2%, 0.5%, and 0.125% nickel, whereas those reporting
severe blistering after only brief contact with jewellery were tested with
0.5%, 0.125%, and 0.03125%. The nickel-containing patches were taped
to the mid-back, removed after 48 h and the response assessed 24 h later.
A positive nickel reaction consisted of erythema with induration at the site
of the patch test, as per the International Contact Dermatitis Research
Group definition (Adams, 1981). By determining the minimum nickel
concentration likely to elicit a mild but confluent nickel reaction (this may
have been one of the three-test doses, or may have been a concentration
above, below or intermediate between the three-test doses), the occurrence
of larger or vesicular reactions was minimized during subsequent patch
testing.
Nickel-induced erythema was measured with a reflectance spectrometer
(Diastron, Hampshire, U.K.), with subjects resting in the prone position.
The nickel-induced erythema index (EI) at each test site was calculated as
the difference between the mean of four erythema readings at the nickel
test site and the mean of four readings taken from skin adjacent to each
test site.
UV source SSUV irradiation was provided by a 1000 W ozone-free
xenon arc lamp with a collimated 7.5 cm2 beam (Oriel, Stratford, CT).
The lamp emission was filtered by two 280–400 nm dichroic mirrors (to
attenuate the visible and infrared component) and an atmospheric attenu-
ation filter (Oriel) to remove UVC (,290 nm) and modify the UVB
spectrum so that it more closely approximated sunlight. This was the solar-
simulated spectrum (Fig 1). By substituting a UVB and UVC blocking
filter (Oriel) for the atmospheric attenuation filter, a primarily UVA-only
spectrum was produced. In order to generate a UVB-only spectrum (with
only minimal residual UVA), two 260–320 nm dichroic mirrors (Oriel)
were installed in place of the 280–400 nm dichroics used for the solar-
simulated spectrum. This UVB-only spectrum was also filtered with the
atmospheric attenuation filter.
Spectral irradiance of the lamp, with its different combinations of filters,
was measured at the Commonwealth Scientific and Industrial Research
Figure 1. The SSUV spectrum of the Oriel Solar Simulator
approximates solar UV (absolute daily spectral exposure doses). The
solar spectrum here represents 6 min exposure to the standard sun UV
spectrum as defined in the European Cosmetic Toiletry and Perfumery
Association Sun Protection Factor Test Method (1994). This spectrum is
a rounded average of the solar spectra of Sayre et al (1990) and Diffey and
Robson (1989) (cloudless sky at low altitude, at latitudes 35°N and 40°N,
respectively). The SSUV, UVB, and UVA spectra represent the subjects’
absolute levels of daily UV exposure.
Organization (Sydney, Australia). The integrated irradiance of the solar-
simulated spectrum at the skin surface was 5.1 mW per cm2 UVB
(290–320 nm), 9.7 mW per cm2 UVAII (320–340 nm) and 26.6 mW per
cm2 UVAI (340–400 nm). The daily dose of SSUV comprised 143 mJ per
cm2 UVB, 271 mJ per cm2 UVAII and 745 mJ per cm2 UVAI.
The UVA spectrum had an irradiance of 5.9 µW per cm2 of UVB
(. 315 nm), 3.3 mW per cm2 UVAII and 24.4 mW per cm2 of UVAI;
the daily UV dose given with this ‘‘UVA-only spectrum’’ was 233 mJ per
cm2 UVAII (i.e., approximately equal to that within the solar-simulated
spectrum) and 1709 mJ per cm2 UVAI. There was also a small amount of
UVB present in the ‘‘UVA-only’’ spectrum (daily UVB exposure was
0.42 mJ per cm2 UVB; 0.41 mJ per cm2 of this UVB radiation was
. 315 nm).
The ‘‘UVB-only’’ spectrum had an irradiance of 5.1 mW per cm2 UVB,
4.4 mW per cm2 UVAII and 1.9 mW per cm2 UVAI. The daily dose of
UVB from this source was 144 mJ per cm2, with a small amount of residual
UVA (123 mJ per cm2 UVAII and 53 mJ per cm2 UVAI).
The irradiance of the lamp output was monitored at least daily with an
IL1350 broadband radiometer using SED 038 (UVA) and SED 240 (UVB)
detectors (International Light, Newburyport, MA). All subjects in each
group were irradiated with the same daily doses of UV regardless of skin
color or MED.
UV irradiation Using the SSUV source, the MED of the skin of the
lateral mid-back was determined for each subject in the SSUV and UVA
studies as the lowest UV dose at which erythema was observed. In the
UVB-only study, the MED was determined using the UVB-only source.
Separate groups of volunteers were used for the different experiments
with their different irradiation protocols. In each group, the skin of one
or both sides of the mid-back was irradiated within a 4 3 6 cm template,
which comprised up to six irradiated sites. The position of the various
unirradiated and irradiated patches within the template was randomly
varied in each subject so as to counteract any potential anatomic influence
on the intensity of nickel CHS responses.
In the first group (irradiation protocol 1), subjects were irradiated with
both SSUV and UVA, daily for 5, 4, and 3 d to different areas of their
backs. There were thus six irradiated sites: three receiving SSUV and three
receiving UVA for 3, 4, and 5 d. The sites irradiated for 5 d received UV
daily from Monday to Friday in 1 wk. The sites irradiated for 4 d received
UV on Monday, Wednesday, Thursday, and Friday of that same week,
whereas the sites irradiated for 3 d received UV on Tuesday, Thursday,
and Friday. In all cases, nickel patches were placed on each of the irradiated
segments on Friday, immediately after the final UV exposure. Patches were
simultaneously placed on adjacent, unirradiated skin in each subject to
serve as immunologically intact controls. The patches were left in place
for 48 h, and the resulting nickel CHS measured with the erythema meter
24 h later, on the following Monday.
The second group of volunteers (irradiation protocol 2) were also
irradiated with SSUV and UVA at different sites, but for 1 d (Thursday)
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Table I. Subject characteristics
3, 4, 5 d 1, 2 d 1–5 d 1–4 wk
SSUV, UVA (protocol 1) SSUV, UVA (protocol 2) UVB (protocol 3) SSUV, UVA (protocol 4)
No. eligible subjects 16 16 16 5
No. excluded 1 3 1 1
Mean age (y) 26 34 32 29
Range 18–37 18–62 20–53 23–41
Mean MED (mJ per cm2 UVB) 269 224 306 167
Range 128–717 108–307 108–358 128–538
No. subjects of skin typea
I 0 1 0 1
II 6 5 3 1
III 6 8 8 3
IV 3 2 5 0
V 1 0 0 0
Mean EI of unirradiated control site 80.1 68.1 65.3 61.6
aFitzpatrick’s classification (1988).
and 2 d (Wednesday and Thursday) only. Nickel patches were simultan-
eously applied to the different sites on Friday (24 h after the final irradiation)
and measured the following Monday.
A third group of volunteers (irradiation protocol 3) was irradiated daily
with UVB only, for 5, 4, 3, 2, and 1 d to different sites. The timing of
this irradiation protocol was identical to that described in protocols 1 and
2 combined, with nickel challenge always being performed on Friday and
the CHS response assessed the following Monday.
The fourth group of six subjects (irradiation protocol 4) was irradiated
with SSUV and UVA at different sites for 1, 2, 3, and 4 wk. Each week,
the various sites were irradiated on 4 d (Monday, Wednesday, Thursday,
and Friday). The sites irradiated for 4 wk received this weekly irradiation
protocol from week 1, for the 4 consecutive weeks of the experiment.
The sites receiving 3 wk UV began their UV exposure in week 2, and
the sites receiving 2 wk’ UV began their exposure in week 3. The sites
receiving only 1 wk UV did not begin their exposure until week 4. Hence
the various sites, with UV exposures over 1–4 wk, all had their final UV
exposures on the same day (Friday of week 4), with nickel patch testing
done immediately thereafter.
Analysis of data The magnitude of immunosuppression at each test site
was determined by comparing the nickel-induced erythema (EI) of the
irradiated test sites with nickel-induced erythema at the unirradiated
control site:
Immunosuppression (∆EI) 5
EI (unirradiated control) – EI (irradiated test site)
Statistical comparisons were made by comparing nickel-induced erythema
at control sites with nickel-induced erythema at test sites in each subject
via paired two-tailed Student’s t-tests. Results were considered significant
if p , 0.05, and are presented as mean 6 SEM. Correlations, using linear
regression analysis, were also considered significant if p , 0.05.
RESULTS
Nickel-allergic subjects None of the volunteers suffered signi-
ficant adverse effects from the nickel patch testing, and all but one
completed the study. This subject did not complete the study for
unrelated reasons. Six subjects were excluded from the results
because of insufficient nickel reaction at the unirradiated control
site (i.e., lack of confluent induration), despite an acceptable
reaction to the initial patch test. Characteristics of the eligible
subjects in each group are shown in Table I.
The UVB source was erythemally equivalent to the solar-
simulated UV source Twelve subjects of mean age 31 y (range,
20–58 y) were MED tested with both the solar-simulated source
and the UVB-only source. Their mean SSUV MED was
288 6 46 mJ per cm2 UVB (with 2.1 J per cm2 accompanying
UVA), whereas their mean MED with the UVB source was
290 6 30 mJ per cm2 UVB (with 354 mJ per cm2 UVA).
Correlation of the volunteers’ SSUV MED with their UVB MED
gave an r-value of 0.95 (t 5 9.9; p , 0.001).
Figure 2. Immunosuppression of nickel CHS reached maximal
levels with 2 d of SSUV and 3 d of UVA exposure. Immunosuppression
is shown here as the mean reduction in nickel-induced erythema with
each irradiation protocol (∆EI). These data represent the results from two
separate groups of 16 volunteers: one group (a) received 3, 4, and 5 d
exposure to SSUV and UVA to different areas of their backs (i.e., six
irradiated sites as per protocol 1), and the second group (b) received 1 and
2 d exposure (protocol 2). After the final irradiation on Friday, nickel
patches were applied to all irradiated sites, and also to adjacent, unirradiated
sites serving as controls (mean 6 SEM; two-tailed Student’s t-test,
comparison of unirradiated control sites with irradiated sites).
The acute immunosuppressive effects of SSUV and UVA are
maximal with 2 and 3 d UV, respectively In the group
exposed to 3, 4, and 5 d of SSUV and UVA (protocol 1), significant
mean immunosuppression (∆EI) of 19.9 6 5.8 was observed with
3 d of SSUV exposure (n 5 16; p , 0.01)(Fig 2a). With 4 d of
SSUV exposure, immunosuppression peaked at ∆EI of 28 6 5.6
(equivalent to µ34% immunosuppression; p , 0.001) and with
5 d of SSUV, mean ∆EI was 25.1 6 5.8 (p , 0.001). In contrast,
UVA-induced immunosuppression was maximal with 3 d of expo-
sure (mean ∆EI 24.7 6 4.6; p , 0.0001) and then declined with
4 and 5 d of exposure to 10.1 6 5.3 and 7.9 6 4.6, respectively
(both NS; p . 0.05).
In the group of volunteers irradiated with protocol 2, there was
significant immunosuppression (∆EI) of 13.7 6 6 and 26.6 6 7.4
with 1 and 2 d SSUV, respectively (n 5 16; p , 0.05; p , 0.01)
(Fig 2b). With 2 d of UVA exposure, ∆EI was 14.7 6 6.4
(p , 0.05) and with 1 d mean ∆EI was 15.4 6 5.2 (p , 0.01).
Thus SSUV and UVA caused immunosuppression over different
time-courses. Immunosuppression due to UVA peaked after 3 d
and then became refractory to further UVA doses, whereas immuno-
suppression due to SSUV reached near-maximal levels after two
exposures and remained high after five exposures.
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Figure 3. UVB-induced suppression of nickel CHS has a time-
course parallel to that of SSUV. Immunosuppression is shown as the
mean reduction in nickel-induced erythema (∆EI) at sites exposed to 1, 2,
3, 4, and 5 d of UVB (protocol 3), patch tested on Friday and then
measured 72 h later (Monday). At all time points, immunosuppression due
to SSUV was greater than immunosuppression due to UVB (n 5 16;
mean 6 SEM; two-tailed Student’s t-test).
Figure 4. Chronic irradiation for 1–4 wk with SSUV but not UVA
induces immunosuppression. Five volunteers were exposed to SSUV
and UVA four times per week (Mon, Wed, Thu, Fri) for 1–4 wk as per
protocol 4. After the final UV exposure in the fourth week, nickel patches
were placed on the various irradiated areas and also on adjacent, unirradiated
areas. Nickel-induced erythema at each site was read 72 h later, and
immunosuppression is shown as the mean reduction in nickel-induced
erythema (∆EI) with each UV protocol (n 5 5; mean 6 SEM; two-tailed
Student’s t-test).
UVB is less immunosuppressive than SSUV, but has a similar
time-course of immunosuppression At all time-points, SSUV
was more immunosuppressive than UVB alone, but had an approxi-
mately parallel time-course of immunosuppression (Fig 3). Mean
∆EI with 1–5 d of UVB was 8.6 6 6, 11.9 6 5.1, 11.3 6 5.6,
19.7 6 6.7, and 12.8 6 6.8, respectively, with immunosuppression
reaching significance with 2 d of UVB exposure and maintaining
similar levels with up to 5 d of exposure.
Chronic SSUV but not UVA induces immunosuppres-
sion In the five subjects exposed for 1–4 wk (protocol 4),
significant SSUV-induced immunosuppression was observed after
1, 2, and 3 wk of exposure (mean ∆EI 21.2 6 3.3, 33.4 6 11.7,
and 25.2 6 6.1, respectively; p , 0.01, p , 0.05, and p , 0.05),
and relatively high but nonsignificant immunosuppression with
4 wk (mean ∆EI 26.8 6 10; NS, p . 0.05). After 1 wk (i.e., 4 d)
of UVA exposure, significant immunosuppression was not observed.
UVA also failed to induce immunosuppression at sites exposed for
2, 3, and 4 wk (Fig 4).
Elicitation of nickel CHS in unirradiated skin is not impaired
by irradiation of adjacent skin In 21 of the 48 subjects in
protocols 1–3, the concentration of nickel used in the final patch
test (i.e., following UV exposure) was the same as that eliciting a
minimal but confluent reaction in the initial patch test (i.e., without
prior UV exposure). This group of 21 subjects comprised five from
protocol 1, nine from protocol 2, and seven from protocol 3. In
the remainder of subjects, the nickel concentration used for final
patch testing was different from those causing confluent responses
in the initial patch test array.
When the initial patch tests (i.e., prior to commencement of the
UV exposures) were compared with the unirradiated control patch
tests (i.e., after the UV exposures), the intensity of nickel CHS at
the unirradiated sites was not significantly affected by exposure of
adjacent skin to the various UV protocols Thus, these UV protocols
caused local but not systemic immunosuppression.
DISCUSSION
In order to compare more directly the immunosuppressive effects
of low-dose SSUV and its UVA and UVB components, we used
various filters to modify the same xenon arc lamp. Although the
doses of UVA and UVB delivered separately were reasonably well
matched with the doses delivered within the SSUV irradiation,
none of the filters provided a clean, ‘‘vertical’’ cut-off between
wavebands. The filter used to generate the UVA spectrum not
only blocked UVB transmission, but also attenuated the shorter-
wavelength UVAII. Longer daily irradiation with the UVA source
was therefore required to maintain equivalent amounts of UVAII
in the UVA and SSUV spectra. Whereas this achieved almost
identical total daily UVAII exposure in the two protocols, it also
meant that the UVA sites received twice the UVAI of the SSUV sites.
Our UVB and SSUV spectra were erythemally equivalent and
well-matched in the waveband 290–310 nm, although the UVB
spectrum contained 6% less 310–320 nm radiation than the SSUV
spectrum. The dichroic mirrors used to produce the UVB spectrum
removed most but not all of the UVA: the ‘‘UVB’’ spectrum
contained some UVA, predominantly UVAII, but this amount was
less than 10% of that in the UVA spectrum and 17% of that in the
SSUV spectrum.
Using suberythemal UV doses, equivalent to approximately
6 min of midday summer sun exposure (Diffey and Robson, 1989;
Sayre et al, 1990) and 0.6 of the volunteers’ mean solar-simulated
MED, we found that elicitation of nickel CHS was significantly
suppressed by even single exposures to SSUV and UVA, and by
two exposures to UVB, but that the different wavebands exerted
their maximal immunosuppressive effects at different time points
and to different extents.
SSUV-induced immunosuppression reached significance after
even one exposure, increased to near-maximal levels after two
exposures and remained high at all time points up to 4 wk. In
contrast, UVA-induced immunosuppression was significant after
one and two exposures, but peaked with three exposures and then
rapidly diminished. With 4 d–4 wk of UVA exposure, significant
immunosuppression was not observed. Our UVA spectrum con-
tained no wavelengths less than 315 nm, and the small amount of
UVB present (315–320 nm) was less than 0.3% of that in the
SSUV and UVB spectra. The acute immunosuppressive effects of
our UVA source therefore cannot be attributed to ‘‘contaminat-
ing’’ UVB.
The different time-courses of SSUV and UVA-induced immuno-
suppression suggest different mechanisms of action. Whereas both
UVA and UVB are known to have genetic effects, they appear to
regulate differentially the expression of tumor suppressor and
apoptosis inhibiting genes (Wang et al, 1998). Although UVA and
UVB reduce the number and function of Langerhans cells in
human skin (Aberer et al, 1981), UVAI was found by Baadsgaard
et al (1989) to cause only a transient decrease in antigen-presenting
cell capacity: despite significant reduction immediately after expo-
sure to high-dose UVAI, Langerhans cell activity had fully recovered
3 d later. LeVee et al (1997) found that exposure to UVAII caused
an influx of novel CD11 DR1 CD361 CD11b1 Langerhans cells,
and suggested that this may represent a migrant subset repopulating
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the epidermis after an initial reduction in density. This novel subset
was not identified after irradiation with UVB. Rapid recovery of
antigen-presenting activity 3 d after high-dose UVA may explain
the findings of Skov et al (1997) that primary sensitization of human
volunteers to diphenylcyclopropenone was not reduced 3 d after
exposure to a single, erythemal dose of UVAI. Further, early
recovery of immune function is consistent with our observation of
significant immunosuppression after 3 d but not after 4 d of low-
dose UVA.
Comparison of the acute immunosuppressive time-courses of
SSUV and UVB revealed an approximately parallel relationship.
Both spectra produced high levels of immunosuppression after 2 d,
although SSUV was more immunosuppressive than UVB at all
time points. This is most likely to have been due to the UVA (and
perhaps predominantly the UVAII) content of the SSUV spectrum.
We observed that with 2, 4, and 5 d of exposure, the ‘‘UVB-only’’
and ‘‘UVA-only’’ protocols seemed to have roughly additive effects
(i.e., addition of UVB-induced and UVA-induced immunosuppres-
sion after 2, 4, and 5 d of exposure approximated the level of
immunosuppression observed after two, four, and five exposures
to SSUV, respectively). With three exposures, however, UVA and
SSUV seemed to have effects trending in opposite directions: UVA-
induced immunosuppression was maximal, whereas SSUV-induced
immunosuppression was slightly lower than with either two or
four exposures. This implies that, at least at certain critical time-
points, the immunosuppressive effects of UVA and UVB are not
simply additive but may reflect interactions between the different
wavebands.
It is unclear why the immunosuppressive time-course of SSUV
(i.e., UVB 1 UVA) paralleled that of UVB, with a slight decrease
in immunosuppression after three exposures, rather than following
the increase observed with three UVA exposures. One possible
explanation is that the immunosuppressive effects of UVA, and
particularly UVAI, may be determined by the total, cumulative
UVA dose, rather than the timing or fractionation of its delivery.
In this study, the dose of UVAI contained in three exposures to
the UVA spectrum (µ5.1 J per cm2) was equivalent to the total
dose of UVAI contained in µ7 exposures to the SSUV spectrum
(µ5.2 J per cm2). This could account for the increased immunosup-
pression seen with 2 wk of SSUV (i.e., eight exposures). Once the
cumulative dose of UVAI reaches a critical level, it might then
induce the adaptive mechanism(s) preventing immunosuppression
by continued irradiation.
Our results contrast with previous, murine studies which have
shown enhanced elicitation of CHS after exposure to relatively
low, acute doses of UVB (Grabbe et al, 1995) as well as higher,
erythemal UVB exposures (Polla et al, 1986). This may reflect
different UV effects in mice and humans; our findings confirm
those of Sjo¨vall and Christensen (1986), who reported suppression
of nickel CHS by chronic exposure of human subjects to UVB
but not UVA. The UVA in their study was delivered four times
per week for 3 wk, causing a small but not significant decrease in
clinical assessments of the nickel reactions (12%). Our 3 wk UVA
protocol, which used UVA doses approximately nine times smaller,
resulted in a nonsignificant decrease in EI of 24% in our small
group of five subjects. We and others have found that measurement
of nickel CHS with the reflectance erythema meter provides a
more sensitive, reproducible, and dose–response assessment of small
changes in CHS intensity than clinical assessment of the responses
(Memon and Friedmann, 1996; Damian et al, 1997) so it may be
that Sjo¨vall and Christensen’s (1986) results would have been more
similar to ours had they used an erythema meter. Alternately, it
may be that higher doses of long wavelength UVA are immunopro-
tective, as suggested by Reeve et al (1998).
A possible protective mechanism of UVAI is the induction of
the anti-oxidant ferritin in the dermis and epidermis. Applegate
et al (1998) found that in vivo ferritin levels in human skin are
markedly increased by UVAI, and to a lesser extent by UVAII, but
not SSUV. Reeve et al (1998) have suggested that UVAI might be
protective by inducing a photoproduct which competitively inhibits
cis-urocanic acid. Thus acute UVA exposure may initially be
immunosuppressive but then induce protective mechanisms. In our
study, daily exposures to the SSUV and UVA spectra comprised
equivalent doses of UVAII, but different doses of UVAI: the UVAI
content of our UVA spectrum was double that of the SSUV
spectrum. This ‘‘excess’’ long wavelength radiation may have
prevented immunosuppression by continued UV exposure, and
accounted for the short duration of our UVA-induced immunosup-
pression.
In contrast to our results, Moyal et al (1997) found that high-
dose, chronic SSUV and UVA delivered to large surface areas of
the body caused not only local but also systemic suppression of
DTH to recall antigens in humans. With our low-dose UV
protocol, using SSUV doses 2.5 times lower and UVA doses 15
times lower than Moyal’s, delivered to a total irradiated surface
area 200 times smaller, systemic immunosuppression did not occur.
The final nickel patch test reactions adjacent to irradiated skin were
not smaller than the initial, pre-irradiation reactions. Cooper et al
(1992) used similar, suberythemal doses of UVB as in our study,
delivered to a comparable surface area, and found no evidence of
systemic suppression of the induction of CHS. Only when a much
larger, 4 MED dose of unfiltered UVB was used was there reduced
immunization through a distant, unirradiated site.
Previous work done by our group suggested that, in humans,
acute low-dose UV exposure may be more immunosuppressive
than chronic exposure. We found that 1 wk exposure to sub-
erythemal SSUV caused greater suppression of DTH to tuberculin
purified protein derivative in humans than 1 mo exposure (Damian
et al, 1998). This differs from our findings that acute and chronic
SSUV were equally able to suppress CHS, and supports previous
suggestions that CHS and DTH responses are differentially modified
by UV exposure (Kripke and Morison, 1986; Kim et al, 1990),
possibly because of different penetration of UVB and UVA into
the skin. Again, our results with chronic UV and both CHS and
DTH to recall antigens suggest that there are adaptive mechanisms
within the skin which limit the immunosuppressive effects of long-
term UV exposure. Although subject numbers were small in this
chronic UV study, the levels of immunosuppression induced after
four exposures to both SSUV and UVA were comparable with the
levels of immunosuppression detected in the larger, acute study.
We conclude that local CHS responses to recall antigens can be
significantly suppressed by even small, suberythemal doses of UV,
and that the immune effects of UVA are dependent on the amount,
wavelength, and timing of UVA exposure.
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